Anti-inflammatory activity of roflumilast. Study on the efficacy of oral roflumilast (500 μg/d) over 4 weeks on sputum neutrophils in chronic obstructive pulmonary disease (COPD) patients. A double-blind, randomized, placebo-controlled, 2-period, cross-over study

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A phase 2, double-blind, randomized, placebo-controlled, two-period crossover study in subjects with chronic obstructive pulmonary disease (COPD).